Cargando…
Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review
INTRODUCTION: Olanzapine (OLZ) is a second generation antipsychotic that is approved for the treatment of schizophrenia, bipolar disorder type 1 as monotherapy (acute manic or mixed episodes, maintenance), or as an add-on to lithium or valproate (manic or mixed episodes). It is one of the most effec...
Autores principales: | Laguado, S. Andrea, Saklad, Stephen R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Psychiatric Pharmacists
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405627/ https://www.ncbi.nlm.nih.gov/pubmed/36071739 http://dx.doi.org/10.9740/mhc.2022.08.254 |
Ejemplares similares
-
Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?
por: Peckham, Alyssa M., et al.
Publicado: (2018) -
Comment on “Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review”
por: Todtenkopf, Mark S., et al.
Publicado: (2023) -
Pharmacogenetics of antiepileptic drugs: A brief review
por: Parker, D., et al.
Publicado: (2016) -
A review of pharmacokinetic and pharmacodynamic interactions with antipsychotics
por: Wijesinghe, Ruki
Publicado: (2016) -
A review of significant pharmacokinetic drug interactions with antidepressants and their management
por: Hoffelt, Charity, et al.
Publicado: (2016)